Tassos Gianakakos | President, CEO & Director |
Jay Edelberg | SVP, Clinical Development |
William Fairey | Chief Commercial Officer & EVP |
Taylor Harris | CFO |
Anupam Rama | JPMorgan Chase & Co. |
Tazeen Ahmad | Bank of America Merrill Lynch |
Ritu Baral | Cowen and Company |
James Birchenough | Wells Fargo Securities |
Alethia Young | Cantor Fitzgerald & Co. |
Martin Auster | Crédit Suisse |
Etzer Darout | Guggenheim Securities |
Jeff Hung | Morgan Stanley |
Keith Tapper | Citigroup |
Gobind Singh | BMO Capital Markets |
David Nierengarten | Wedbush Securities |
Good afternoon, everyone. I'm Michelle Corral, MyoKardia's Head of Corporate Communications and Investor Relations. Welcome to today's call to review second quarter results and recent business updates. A press release summarizing Q2 results has been posted to the Investors section of the MyoKardia website. Leading today's call is MyoKardia's CEO, Tassos Gianakakos.